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Knowing the usual clinical practice is relevant for evaluations in health care and economic policies of management of hypertension.
This study aimed to describe the usualmanagement of hypertension in the Brazilian primary healthcare system through a systematic
review and meta-analysis. The search of population-based studies conducted in Brazil was undertaken using PubMed, EMBASE,
and Brazilian databases. Eligible studies were those conducted in adults with hypertension (blood pressure (BP) ≥ 140/90mmHg or
using BP lowering drugs).Three datasets’ data were analyzed: SESI study (in Brazilian workers); HIPERDIA (Brazilian Registration
andMonitoring of Hypertensive and Diabetic Patients Program); and a population-based study. Meta-analysis has been performed
using the fixed and random effect models. A total of 11 studies or data sets were included in the systematic review. Hypertensive
individuals had, on average, 2.6 medical visits annually and 18.2% were on diuretics (𝑛 = 811 hypertensive patients) and 16.2% on
ACE inhibitors (𝑛 = 1768 hypertensive patients). BP control rate ranged from 43.7 to 67.5%; 35.5% had measured total cholesterol
and 36.5% determined fasting plasma glucose in the previous 12 months.Thiazide diuretics and ACE inhibitors were the most used
BP lowering medications as single drugs, but the control rate of hypertension is insufficient.
1. Introduction
Assessment of costs and health outcomes can generate esti-
mates to compare and choose among screening, diagnostic,
or therapeutic strategies, which should be incorporated into
the healthcare system. The endpoint is to achieve maximum
health gains with the available resources, respecting the
expectations of the population covered by the healthcare
system and considering the limited resources [1]. Health
economic evaluations (HEES) are useful tools for managers
and policy makers to choose the best allocation of avail-
able resources, or even about the assimilation of a new
health technology. HEES are particularly useful to decide
on incorporation of new strategies for prevention or control
of noncommunicable diseases. In Brazil, the public health
system, Sistema U´nico de Sau´de (SUS), is based on universal
free access to healthcare to the whole population, with
decentralization provided at all levels, from prevention to
high complexity level, shared by federal, state, and municipal
government [2]. Blood pressure lowering medication are
available at the SUS, freely distributed, and a list of drugs
include thiazide diuretic, beta-blocker, ACE inhibitor, and an
angiotensin receptor blocker (ARB). Health plan physicians
are an alternative placed between the public and private
systems, ranging from partial to full coverage, and usually
with no refund for costs with blood pressure lowering agents.
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HEE is necessary to decide whether new drugs will be made
available by the SUS.
It is estimated that hypertension (HT) affects 28.7%
(95% CI: 26.2–31.4%) of the Brazilian adult population,
with decreasing temporal trend in the rate of hypertension
control [9]. In a meta-analysis of population-based studies,
the control rate was 25% [9]. HT is responsible for significant
global morbidity and mortality [10]. However, there is no
systematic analysis of economic costs for diagnosis, risk
stratification, and treatment of HT in Brazil [11].
A suitable HEE should include the comparison between
the strategy of the Brazilian Guidelines of Hypertension [12]
and the usual practice (status-quo), aiming at the primary
prevention of CVD in patients of primary care. The status-
quo can serve as a baseline for comparisons whenever a new
health strategy is being considered for implementation [13].
Hence, our study aimed to describe the usual practice, in the
context of primary care of the SUS in Brazil, regarding the
diagnosis, risk stratification, and pharmacological treatment
of HT.
2. Methods
2.1. Design and Data Sources. Studies conducted at popula-
tion-based or outpatient, cross-sectional, or cohort studies,
carried out since 2000, were searched in the databases of
PubMed, EMBASE, and population-based databases of the
Brazilian Virtual Health Library (VHL; http://brasil.bvs.br/
en/). The following search strategies were used: VHL
using Descriptors in Health Sciences: “Hipertensa˜o” AND
“Atenc¸a˜o Prima´ria a` Sau´de” AND “Brasil”; on EMBASE
using entrees: “brazil”/exp AND “hypertension”/exp AND
“primary health care”/exp; and on PubMed using MeSH
Terms: ((“Hypertension”[Mesh]) AND “Primary Health
Care”[Mesh]) AND “Brazil”[Mesh]. We also evaluated arti-
cles, whichwere included in ameta-analysis of the prevalence
of hypertension [9], conducted by the authors. Articles that
met the eligibility criteria were included: population-based
cross-sectional or cohort studies performed in participants
with 18 years or more, between 1980 and 2010. We also
incorporated in meta-analysis four sets of data available to
us, regardless of the systematic review searches [14–16].
2.2. Eligibility Criteria for the Review and Screening Process.
Studies conducted in Brazil including patients with HT
treated in any primary care facility affiliated to the SUS or
population-based studies, which reported data in adults with
HT were considered eligible for data extraction. Hospitalized
patients were outside of the scope of this analysis and were
excluded. The search results were handled in a double-
screening process: their titles and abstracts were scrutinized
and those eligible had their full-texts examined. Duplicated
results were excluded. Studies conducted in pregnant women
were excluded.
2.3. Target Population and Variables of Interest. The target
population consisted of Brazilian adults (≥18 years) who
either had blood pressure (BP) ≥ 140/90mmHg or were
on treatment with BP lowering agents (BPLM), enrolled
from the general population or among those who were
undertaking treatment in primary care settings. In order to
collect information on management of patients and ensure
comparability with the Brazilian Guidelines of Arterial
Hypertension [12] and among guidelines [17], the following
variables have been extracted: frequency of medical con-
sultations and type of health insurance (e.g., SUS, private
health plan) used most of the time, number and frequency
of diagnostic tests suggested by this guideline (e.g., ECG,
fasting glucose, and chest X-ray), antihypertensive classes,
clinical characteristics, such as systolic BP (SBP), total and
high-density lipoprotein cholesterol (HDL), and prevalence
of other relevant comorbidities (diabetes mellitus (DM) and
smoking) [18]. The rates of smoking and prevalence of DM
among hypertensive individuals enrolled in the HIPERDIA
(Brazilian Registration and Monitoring of Hypertensive and
Diabetic Patients Program), from May 2002 to April 2012,
were also evaluated [5].
2.4. Data Analysis. Continuous variables with normal dis-
tribution were presented as means and standard deviations
(SD). Binary data were presented as proportions using point
estimates and 95% confidence interval (95% CI). Meta-
analyses were performed with the pooling of means or
proportions: when the same variable of interest wasmeasured
using the same method across studies (e.g., self-reported
diabetes versus fasting plasma glucose) and the same, or
interchangeable, metric (e.g., one laboratory test per month
equals 12 tests per year). Random effects model was mostly
used; however, fixed effect model was employed when non-
significant heterogeneity (𝑝 value ≥ 0.05) was observed, as
measured by Cochran’s 𝑄. The 𝐼2 statistic was employed as
a continuous measure of heterogeneity. Statistical analysis
was performed in the Statistical Package for the Social
Science (SPSS; version 17.0, IL, USA) andmeta-analysis using
Comprehensive Meta-Analysis (software version 2.0; Biostat,
Englewood, NJ). Since this study is entirely descriptive, we
did not formulate nor test any hypothesis.
3. Results
Figure 1 depicts the flow of search results in this review.
The VHL search retrieved 31 results, PubMed 18 results, and
EMBASE another 31 results. EMBASE and VHL retrieved
identical results, which encompassed all the 18 articles
found in PubMed. After the first screening and removal of
overlapping result across databases, 19 articles were deemed
eligible. Four studies reported data on at least one of the
studied variables and were included in the meta-analysis.
There were three available datasets: (i) two datasets from
population-based cross-sectional studies conducted in large
representative samples of two cities from Southern Brazil,
Porto Alegre (capital of the state; SOFT study; 𝑛 = 1858) [6,
7]; (ii) a third dataset was originated from a nationwide cross-
sectional study conducted among 1148 industry workers
(SESI study previously carried out by one of the authors)
[3, 4]; (iii) a nationwide registry of hypertensive and diabetic
patients treated in primary care of SUS (with of 7.3 million
individuals on treatment for hypertension) collected from the
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Figure 1: Flow chart of records retrieved, screened, and included in the systematic review.
HIPERDIA [5]. Another four studies included in a previous
systematic review were considered eligible and, hence, were
added to this meta-analysis along with the three aforemen-
tioned datasets, rendering a total of 11 studies [8, 19–21].
Table 1 shows characteristics of the studies and HIPER-
DIA registry that provided data on clinical characteristics
of individuals with HT according to sex. Studies that have
data on mean systolic blood pressure and blood pressure
control are presented in Table 1 as well. In the SESI study,
men and women had similar SBP, but women had higher
rate of hypertension control than men. In the population-
based studies men and women had similar mean systolic
blood pressure and rates of hypertension control. Higher
prevalence of DMwas observed among patients registered in
HIPERDIA, especially in comparison to the participants of
the SESI study. Smoking prevalence rates were more evenly
distributed across the SESI study, HIPERDIA registry, and
population-based studies, with higher prevalence of current
smokers in men in comparison to women.
Table 2 presents information from seven studies that pro-
vided data on pharmacotherapy, diagnostic tests, andmedical
appointments. Less than half of the hypertensive subjects
were using a single BPLM, and the most common class
of BPLM was thiazide diuretics, followed by angiotensin-
converting enzyme (ACE) inhibitors.Thiazide diuretics com-
bined with ACE inhibitors were the most frequent 2-drug
combination in use (14.9%), followed by thiazides and beta-
blockers (9.4%).
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Table 1: Clinical characteristics of individuals with hypertension from the SESI study, the HIPERDIA registry, and from meta-analyses of
four population-based studies.
Studies and clinical characteristics Mean (±SD)/prevalence (95% CI)
Men Women
SESI study [3, 4]: participants (𝑛) 1034 114
Age (years) 40.6 (11.8) 41.5 (9.2)
Systolic blood pressure (mmHg) 152.5 (15.9) 150.4 (21.7)
Controlled blood pressure 31.8 (26.3–37.7) 56.9 (45.5–67.7)
Total cholesterol (mg/dL) 188.8 (40.0) 196.0 (39.2)
HDL cholesterol (mg/dL) 49.3 (20.9) 56.8 (12.7)
Current smokers 18.3 (15.9–20.7) 15.5 (8.9–22.1)
Diabetes mellitus (DM) 5.6 (4.2–7.0) 3.5 (0.1–6.9)
HIPERDIA registry [5]: participants (𝑛) 2.5 million 4.8 million
Current smokers 21.42 (20.4–22.5) 15.6 (14.7–16.5)
Diabetes mellitus 21.9 (19.8–24.0) 24.9 (22.9–27.0)
Current smokers with DM 6.3 (5.8–6.8) 5.6 (5.2–6.0)
Population-based studies: participants (𝑛) 5064 8126
Systolic blood pressure (mmHg)
Trevisol et al. [6] 146.8 (20.7) 138.9 (22.6)
Dias da Costa et al. [7] 144.5 (8.3) 146.1 (20.7)
Controlled blood pressure
Trevisol et al. [6] 47.8 (39.7–56.1) 43.7 (38.5–49.2)
Dias da Costa et al. [7] 65.7 (53.7–75.9) 67.5 (60.7–73.7)
Moreira et al. [8] 53.0 (46.9–58.4) 52.7 (45.6–58.9)
Current smokers 21.7 (17.2–27.0)‡ 14.8 (10.1–21.0)∗
Diabetes mellitus∗∗ 13.5 (12.5–14.4)† 13.2 (8.3–20.7)††
‡푄 푝 < 0.01; 퐼2 = 90.0%. ∗Data from 7867 women. Q 푝 < 0.01; 퐼2 = 94.1%. †Fixed effect model analysis. 푄 푝 = 0.24; 퐼2 = 27.4%. ∗∗Data from 4912 men
and 7867 women; ††푄 푝 < 0.01; 퐼2 = 87.3%.
Data on diagnostic tests came from one study, and
estimates on most used type of medical services came from
another study. Approximately a third of individuals with
known HT had fasting plasma glucose, serum triglycerides,
total cholesterol, and creatinine level measured in the previ-
ous 12 months. On average, an adult with HT had 2.6 medical
appointments per year, and more than half of subjects who
sought medical appointments used mostly those provided by
the SUS. Figures 2, 3, and 4 are forest plots illustrating con-
tents fromTable 2. Figure 2 shows considerable heterogeneity
among studies, mostly due to the study of Lima et al. [19],
carried out in Rio de Janeiro.
4. Discussion
This systematic review examined all available databases that
provide information on the management of HT among the
Brazilian adult population. Some of them described the com-
pliance with treatment guidelines of the State Health Depart-
ment or provided an opinion on this matter [22, 23]. One
article assessed physicians’ compliance with HT treatment
according to a Municipal Health Department guideline and
detected noncompliance rates of 56.8%, 63.8%, and 54.0%
regarding HT staging, cardiovascular risk classification, and
choice of treatment, respectively [20].
Official data estimate that about 75% of the country’s
population depends exclusively on SUS for health care [24],
but it has not been confirmed by the information from a
population-based study carried out in the city of Pelotas
[7]. The divergence may be explained by at least two biases
from both sources of information: (i) the use of SUS services
probably does not reach the 75% rate for all health conditions;
(ii) recall bias of the medical appointments made in the
previous month by participants of the population-based
study. Nonetheless, the systematic review data derives from
a single city; therefore it is hardly representative of the entire
country.
Medical treatment by use of blood pressure lowering
agents, conversely, was more often reported, so HT treatment
data might be more representative of nationwide clinical
practice within the SUS. Blood pressure control rates among
individuals with HT could not be summarized through the
results of all included studies, but it was reported for three
population-based studies. The rates of controlled hyperten-
sionwere higher than that reported in a previously systematic
review, which identified a pooled control estimate of 24.1%
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Table 2: Frequency of blood pressure lowering medication use, diagnostic tests, and medical appointments among hypertensive subjects.
Prevalence (95% CI)/mean (±SD) Heterogeneity
Status quo 𝑄 𝑝 value 𝐼2
Blood pressure lowering medication (%)
In use of one BPLM 42.7 (28.6–58.1) <0.01 99.0
In use of two BPLM 33.0 (23.7–43.9) <0.01 92.4
Type of BPLM
Thiazide diuretics
Single-drug therapy or combined with another drug 41.1 (26.4–57.6) <0.01 98.3
Single-drug therapy 18.2 (7.4–38.4) <0.01 96.6
Combined with ACEI 14.9 (11.1–19.8) <0.01 84.6
Combined with BB 9.4 (5.7–15.2) <0.01 86.5
Combined with CCB‡ 5.0 (2.4–7.6) NA NA
Angiotensin-converting enzyme inhibitors (ACEI)
Single-drug therapy or combined with another drug 41.1 (20.2–65.7) <0.01 97.7
Single-drug therapy 16.2 (11.6–22.1) <0.01 85.0
Combined with BB† 3.4 (2.5–4.7) 0.07 62.1
Combined with CCB‡ 4.0 (2.1–5.9) NA NA
Beta-blockers (BB)
Single-drug therapy or combined with other BPLM 21.2 (17.3–25.8) <0.01 84.3
Single-drug therapy† 10.0 (8.1–12.3) 0.17 46.2
Combined with CCB‡ 2.3 (0.5–4.1) NA NA
Calcium channel blockers (CCB)
Single-drug therapy or combined with other BPLM 10.0 (7.5–13.3) <0.01 72.4
Single-drug therapy‡ 3.9 (1.6–6.2) NA NA
Angiotensin receptor blockers (ARB)
Single-drug therapy or combined with other BPLM† 2.3 (1.4–3.6) 0.06 71.2
Diagnostic tests and procedures (%) among hypertensive subjects
Previous month testing
Electrocardiography‡ 6.3 (3.9–8.8) NA NA
Any radiography‡ 9.7 (6.8–12.7) NA NA
Any urine test‡ 8.4 (5.6–11.2) NA NA
Any blood test‡ 12.6 (9.3–16.0) NA NA
Direct ophthalmoscopy‡∗ 35.0 (30.2–39.8) NA NA
Previous 12-month testing
Serum potassium‡ 19.5 (13.9–25.2) NA NA
Serum creatinine‡ 31.0 (24.4–29.6) NA NA
Total serum cholesterol‡ 35.5 (28.7–42.3) NA NA
Serum LDL or HDL cholesterol‡ 25.0 (18.3–31.2) NA NA
Serum triglycerides‡ 34.0 (27.3–40.8) NA NA
Fasting plasma glucose‡ 36.5 (29.6–43.4) NA NA
Urine analysis‡ 25.0 (18.8–31.2) NA NA
Medical appointments (%) among hypertensive subjects
Annual mean of medical appointments 2.62 (2.37) 0.5 0
Mostly using Brazilian Health Care System‡ 51.2 (46.1–56.2) NA NA
Mostly using private physicians‡ 20.9 (16.8–25.1) NA NA
Mostly using health plan physician‡ 13.0 (9.6–16.4) NA NA
Mostly using emergency services‡ 1.9 (0.5–3.2) NA NA
Others‡ 13.0 (9.6–16.4) NA NA
†Fixed effect analysis. ‡Based on one study. ∗Since the diagnosis of hypertension; LDL: low-density lipoprotein; HDL: high-density lipoprotein;푄 푝 value and
퐼2–: nonapplicable; that is, only one study provided data; NA: not applicable.
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First author Year City Sample size %
Dias da Costa [7] 2002 Pelotas 262 53.0 46.9–59.0
de Souza [21] 2003 392 46.7 41.8–51.6
Moreira [8] 2009 549 44.6 40.5–48.8
Lima [19] 2009 Rio de Janeiro 3133 18.4 17.1–19.8
Maluf [20] 2010 Curitiba 189 57.0 49.8–63.9
Summary 4525 42.7 28.6–58.1
BPLM: blood pressure lowering medication; 95% CI: 95% condence interval.
95% CI
20 25 30 35 40 45 50 55 60 6515
S o Jos ́e do Rio Preto
S o Paulo
Summary T2 = 0.82, Q < 0.01, I2 = 99.0%
ã
ã
Figure 2: Meta-analysis of proportion of use of one BPLM (in chronological order according to the data collection year).
First author Year City Sample size %
de Souza [21] 2003 São Paulo 392 22.4 18.5–26.8
Moreira [8] 2009 S. José do Rio Preto 549 41.2 37.2–45.4
Lima [19] 2009 Rio de Janeiro 3133 37.2 35.5–38.9
Maluf [20] 2010 Curitiba 189 32.5 26.2–39.5
Summary 4263 33.0 23.7–43.9
BPLM: blood pressure lowering medication; 95% CI: 95% condence interval.
95% CI
20 25 30 35 40 45 50 55 60 6515Summary T
2
= 0.09, Q < 0.01, I
2
= 92.4%
Figure 3: Meta-analysis of proportion of use of two blood pressure lowering medication.
(10.1–47.3%) [9]. The use of thiazide-type diuretics (as single
or combined-drug therapy) was widespread in our analysis.
This is in concordance with the best available evidence of
effectiveness and current guidelines that advocate for the
use of these drugs as first line treatment [12]. However,
considering that there are few absolute contraindications for
the use of diuretics, one may argue that the 41% usage rate
should have been higher. On the other side, thiazide diuretics
are more often used in Brazil than in Denmark, Finland,
Germany, Norway, Sweden, Netherlands [25], Portugal [26],
Spain [27], Mexico [28], and the United States [29]. Among
other antihypertensive drugs, the use of beta-blockers was
similar to that reported in other countries, but the prevalence
of calcium channel blockers (CCB), ACE inhibitors, and
ARBs use was much lower. CCB and ARB were rarely used
to treat HT, since these drugs were not available in the SUS
by the time that most of the studies were conducted. An
ARB agent, by the opposite, was recently incorporated in the
SUS.
Although there are several population-based studies that
evaluated the prevalence of HT all over the country, only
four studies provided information on how participants with
hypertension were treated. The vast majority of these field
studies restricted their assessment to measuring the preva-
lence ofHT and other diseases among the general population,
reporting little or no information with regard to individuals
with HT (mean age of participants with HT, blood pressure
control rates, etc.). Five studies reported the prevalence of
hypertensive patients using one BPLM. The summary esti-
mate of prevalence was reduced due to the weight of a study
performed at a primary care center in Rio de Janeiro [19].
This study introduced heterogeneity due to the variability in
the number of follow-up visits, ranging from 1 to 27, and to
participants who did not use any medication (7.8%) and used
two or more BPLMs (73.8%) and 18.4% who used only one
drug to decrease BP. This study had a major contribution to
the overall results.
Another limitation of the present study is the overall
paucity of publications. This scarcity contrasts with a huge
amount of data on patient management generated every day
inside the SUS [2], with more than 40.4 million medical
appointments recorded in the HIPERDIA registry from
August 2011 to July 2012 [5].
Finally, our data did not cover the years since the new
public program, Farma´cia popular (popular pharmacy), for
delivery of drugs and devices was launched, including the
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Type of therapy First author Year Sample size %
Single-drug or combined
Dias da Costa 2002 262 57.9 51.8–63.7
de Souza 2003 392 32.6 28.2–37.4
Moreira 2009 549 39.9 35.8–44.0
Maluf 2010 189 51.5 44.4–58.5
Santa Helena 2006 565 26.0 22.5–29.8
Hoepfner 2007 415 72.4 67.9–76.5
Trevisol 2012 426 44.4 39.7–49.1
Summary 2798 46.1 33.2–59.6
Single-drug
Dias da Costa 2002 262 27.4 22.3–33.1
Moreira 2009 549 11.6 9.2–14.6
Summary 811 18.2 7.4–38.4
Combined with ACEI
Dias da Costa 2002 262 11.0 7.7–15.4
de Souza 2003 392 11.0 8.3–14.5
Moreira 2009 549 19.5 16.4–23.0
Santa Helena 2006 565 18.6 15.6–22.0
Summary 1768 14.9 11.07–19.7
Combined with BB
Dias da Costa 2002 262 15.0 11.2–19.9
de Souza 2003 392 6.0 4.0–8.8
Moreira 2009 549 8.7 6.7–11.4
Summary 1203 9.4 5.7–15.2
95% CI
ACEI: angiotensin-converting enzyme inhibitors; BB: beta-blockers; 95% CI: 95% condence interval.
25 30 35 40 45 50 55 60 65 70 75 8020
10 15 20 25 30 35 40 45 50 55 60 655
10 15 20 25 30 35 40 45 50 55 60 655
5 10 15 20 25 30 35 40 45 50 55 600
Summary 𝜏2 = 0.44, Q < 0.01, I2 = 97.5%
Summary 𝜏2 = 0.53, Q < 0.01, I2 = 96.6%
Summary 𝜏2 = 0.10, Q < 0.01, I2 = 84.6%
Summary 𝜏2 = 0.20, Q < 0.01, I2 = 86.5%
Figure 4: Meta-analysis of proportion of use of thiazide-based therapy.
subsidized offering of losartan (90% of rebate). Twenty per-
cent of the population is presently covered (http://www.bra-
sil.gov.br/saude/2016/03/aqui-tem-farmacia-popular-atende-
38-milhoes-de-brasileiros-em-10-anos, accessed in Decem-
ber, 22, 2016). The impact of this program in the use of BP
lowering drugs was not captured in the surveys available for
this systematic review.
5. Conclusions
Despite these limitations, the estimates presented by this
review are the best available evidence about the pattern of use
of BP lowering drugs and rate of BP control in Brazil. Further
studies should prospectively collect data to better describe
the impact of new BP lowering agents.Thiazide diuretics and
ACE inhibitors were the most frequently used as a single
drug, and ACE inhibitors were the BP lowering medications
more frequently prescribed, but the rate of hypertension
control is insufficient.
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